News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
_256_384.jpg)
Closing the Loop on single-use plastics
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Biocon has reported consolidated financial results for the period ended December 31, 2021
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Subscribe To Our Newsletter & Stay Updated
